Veronique Calleja

Dr. Veronique Calleja

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
Veronique CallejaVeronique Calleja
Veronique Calleja
MLMichel Laguerre
Michel Laguerre
PPPeter J Parker
Peter J Parker
BLBanafshé Larijani
Banafshé Larijani
Protein kinase B (PKB/Akt) belongs to the AGC superfamily of related serine/threonine protein kinases. It is a key regulator downstream of various growth factors and hormones and is involved in malignant transformation and chemo-resistance. Full-length PKB protein has not been crystallised, thus studying the molecular mechanisms that are involved in its regulation in relation to its structure have not been simple. Recently, the dynamics between the inactive and active conformer at the molecular level have been described. The maintenance of PKB's inactive state via the interaction of the PH and kinase domains prevents its activation loop to be phosphorylated by its upstream activator, phosphoinositide-dependent protein kinase-1 (PDK1). By using a multidisciplinary approach including molecular modelling, classical biochemical assays, and Förster resonance energy transfer (FRET)/two-photon fluorescence lifetime imaging microscopy (FLIM), a detailed model depicting the interaction between the different domains of PKB in its inactive conformation was demonstrated. These findings in turn clarified the molecular mechanism of PKB inhibition by AKT inhibitor VIII (a specific allosteric inhibitor) and illustrated at the molecular level its selectivity towards different PKB isoforms. Furthermore, these findings allude to the possible function of the C-terminus in sustaining the inactive conformer of PKB. This study presents essential insights into the quaternary structure of PKB in its inactive conformation. An understanding of PKB structure in relation to its function is critical for elucidating its mode of activation and discovering how to modulate its activity. The molecular mechanism of inhibition of PKB activation by the specific drug AKT inhibitor VIII has critical implications for determining the mechanism of inhibition of other allosteric inhibitors and for opening up opportunities for the design of new generations of modulator drugs. A critical protein in cell-signalling pathways, called protein kinase B, regulates many aspects of cell biology from metabolism to proliferation and survival, by modifying other proteins with the addition of a phosphate group. Hence, deregulation of its activity has acute consequences on cell function. Increased activity of a tumour-promoting form of protein kinase B or of upstream regulatory proteins has been observed in tumours, while impaired protein kinase B function has been linked to diabetes. Therefore, understanding the molecular mechanism of protein kinase B activation will help reveal how its activity might be regulated to limit disease progression. Toward this end, we studied how protein kinase B structure relates to its function, to identify molecular mechanisms regulating its kinase activity, modifying its cellular localization, and altering its binding to other proteins. By determining the spatial organization of different regions of the protein in inactive protein kinase B, we discovered a cavity at the interface of two distinct functional regions of the inactive form. We also localized the C-terminal end of the protein to the apex of the cavity, suggesting a role of this domain in regulating the inactive form of the protein. This represents a novel example of negative regulation by inhibition across these different regions of the protein. From these findings, we elucidated the mechanism of action of a highly specific protein kinase B inhibitor, AKT inhibitor VIII. We determined that simultaneous binding of the inhibitor to the two different functional regions, through the cavity, “locks” protein kinase B in an inactive conformation and prevents regulatory proteins from accessing the C-terminal domain.

3 April 2007 in PLOS Biology
Verified
Journal Article
Open access
PDF file
Veronique CallejaVeronique Calleja
Veronique Calleja
DADamien Alcor
Damien Alcor
MLMichel Laguerre
Michel Laguerre
Jongsun ParkJongsun Park
Jongsun Park
BVBorivoj Vojnovic
Borivoj Vojnovic
BLBanafshé Larijani
Banafshé Larijani
Protein kinase B (PKB/Akt) is a pivotal regulator of diverse metabolic, phenotypic, and antiapoptotic cellular controls and has been shown to be a key player in cancer progression. Here, using fluorescent reporters, we shown in cells that, contrary to in vitro analyses, 3-phosphoinositide–dependent protein kinase 1 (PDK1) is complexed to its substrate, PKB. The use of Förster resonance energy transfer detected by both frequency domain and two-photon time domain fluorescence lifetime imaging microscopy has lead to novel in vivo findings. The preactivation complex of PKB and PDK1 is maintained in an inactive state through a PKB intramolecular interaction between its pleckstrin homology (PH) and kinase domains, in a “PH-in” conformer. This domain–domain interaction prevents the PKB activation loop from being phosphorylated by PDK1. The interactive regions for this intramolecular PKB interaction were predicted through molecular modeling and tested through mutagenesis, supporting the derived model. Physiologically, agonist-induced phosphorylation of PKB by PDK1 occurs coincident to plasma membrane recruitment, and we further shown here that this process is associated with a conformational change in PKB at the membrane, producing a “PH-out” conformer and enabling PDK1 access the activation loop. The active, phosphorylated, “PH-out” conformer can dissociate from the membrane and retain this conformation to phosphorylate substrates distal to the membrane. These in vivo studies provide a new model for the mechanism of activation of PKB. This study takes a crucial widely studied regulator (physiology and pathology) and addresses the fundamental question of the dynamic in vivo behaviour of PKB with a detailed molecular mechanism. This has important implications not only in extending our understanding of this oncogenic protein kinase but also in opening up distinct opportunities for therapeutic intervention. Regulation of intracellular signaling depends on the precise operation of molecular switches such as kinases and phosphatases. Disruption of their activities leads to inappropriate cellular proliferation, growth, and survival. Protein kinase B (PKB) is a critical kinase that regulates events downstream of growth factor receptors. It is also involved in human cancer, where its overexpression induces malignant transformation. We studied the molecular mechanisms of PKB's interaction with its upstream regulator, 3-phosphoinositide–dependent protein kinase 1 (PDK1). By using a fluorescent probe, we monitored the conformational changes of PKB in cells using Förster resonance energy transfer detected by fluorescence lifetime imaging microscopy. Applying this approach, we show that PKB and PDK1 are found as complexes in the cytoplasm. Despite this proximity to its regulator, we show that PKB remains inactive through an intramolecular interaction of its pleckstrin homology (PH) domain and kinase domain. We refer to this inactive state as the “PH-in” conformer. Following growth factor activation, PKB changes conformation to the “PH-out” conformer and is phosphorylated by PDK1. The active “PH-out” conformer dissociates from the plasma membrane to phosphorylate downstream proteins. Our in vivo studies provide a new model for the mechanism of PKB.

5 June 2011 in Nature Cell Biology
Verified
Journal Article
Closed access
CJCarine Joffre
Carine Joffre
RBRachel Barrow
Rachel Barrow
LMLudovic Ménard
Ludovic Ménard
Veronique CallejaVeronique Calleja
Veronique Calleja
IHIan R. Hart
Ian R. Hart
Stephanie KermorgantStephanie Kermorgant
Stephanie Kermorgant

1 October 1996 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Jean-françois TantiJean-françois Tanti
Jean-françois Tanti
TGThierry Grémeaux
Thierry Grémeaux
SGSophie Grillo
Sophie Grillo
Veronique CallejaVeronique Calleja
Veronique Calleja
AKAnke Klippel
Anke Klippel
YMYannick Le Marchand-Brustel
Yannick Le Marchand-Brustel
Insulin stimulates glucose transport in its target cells by recruiting the glucose transporter Glut 4 from an intracellular compartment to the cell surface. Previous studies have indicated that phosphatidylinositol 3-kinase (PI 3-kinase) is a necessary step in this insulin action. We have investigated whether PI 3-kinase activation is sufficient to promote Glut 4 translocation in transiently transfected adipocytes. Rat adipose cells were cotransfected with expression vectors that allowed transient expression of epitope-tagged Glut 4 and a constitutively active form of PI 3-kinase (p110*). The expression of p110* induced the appearance of epitope-tagged Glut 4 at the cell surface at a level similar to that obtained after insulin treatment, whereas a kinase-dead version of p110* had no effect. The p110* effect was observed over a wide range of the transfected cDNA. When subcellular fractionation of adipocytes was performed, p110* was found, similar to the endogenous PI 3-kinase, enriched in the low density microsomal compartment, which also contains the Glut 4 vesicles. This could suggest that a specific localization of PI 3-kinase in this compartment is required for the action on Glut 4. The observations made with PI 3-kinase are in contrast with those seen with the MAP kinase cascade. Indeed, a constitutively active form of MAP kinase kinase had no effect on Glut 4 translocation in basal conditions. At the highest degree of expression, the constitutively active form of MAP kinase kinase slightly inhibited the insulin stimulation of Glut 4 translocation. Taken together, our results indicate that Glut 4 translocation can be efficiently promoted by an active form of PI 3-kinase but not by the activation of the MAP kinase pathway.

15 May 2003 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
Veronique CallejaVeronique Calleja
Veronique Calleja
SASimon M. Ameer-Beg
Simon M. Ameer-Beg
BVBorivoj Vojnovic
Borivoj Vojnovic
RWRudiger Woscholski
Rudiger Woscholski
JDJulian Downward
Julian Downward
BLBanafshé Larijani
Banafshé Larijani
To be able to detect in situ changes in protein conformation without perturbing the physiological environment would be a major step forward in understanding the precise mechanism occurring in protein interaction. We have developed a novel approach to monitoring conformational changes of proteins in intact cells. A double-labelled fluorescent green fluorescent protein–yellow fluorescent protein (GFP–YFP) fusion protein has been constructed, allowing the exploitation of enhanced-acceptor-fluorescence (EAF)-induced fluorescence resonance energy transfer (FRET). Additionally, a novel fusion partner, YFPdark, has been designed to act as a sterically hindered control for EAF-FRET. Any conformational changes will cause a variation in FRET, which, in turn, is detected by fluorescence lifetime imaging microscopy (‘FLIM’). Protein kinase B (PKB)/Akt, a key component of phosphoinositide 3-kinase-mediated signalling, was selected for this purpose. Although conformational changes in PKB/Akt consequent to lipid binding and phosphorylation have been proposed in models, its behaviour in intact cells has not been tractable. We report here that platelet-derived-growth-factor (‘PDGF’) stimulation of NIH3T3 cells expressing the GFP–Akt–YFP construct resulted in a loss of FRET at the plasma membrane and hence a change in PKB/Akt conformation. We also show that the GFP–Akt–YFP construct conserves fully its functional integrity. This novel approach of monitoring the in situ conformational changes has broad application for other members of the AGC kinase superfamily and other proteins.

1 March 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VBVéronique Baron
Véronique Baron
Veronique CallejaVeronique Calleja
Veronique Calleja
PFPatricia Ferrari
Patricia Ferrari
FAFrançoise Alengrin
Françoise Alengrin
EOEmmanuel Van Obberghen
Emmanuel Van Obberghen
The focal adhesion kinase p125Fak is a widely expressed cytosolic tyrosine kinase, which is involved in integrin signaling and in signal transduction of a number of growth factors. In contrast to tyrosine kinase receptors such as the platelet-derived growth factor and the hepatocyte growth factor receptors, which induce p125Fakphosphorylation, insulin has been shown to promote its dephosphorylation. In this study, we compared p125Fakphosphorylation in insulin-stimulated cells maintained in suspension or in an adhesion state. We found that, in nonattached cells, insulin promotes p125Fak phosphorylation, whereas dephosphorylation occurred in attached cells. This was observed in Rat-1 fibroblasts overexpressing the insulin receptor, as well as in Hep G2 hepatocytes and in 3T3-L1 adipocytes expressing more natural levels of insulin receptors. Insulin-induced p125Fak phosphorylation correlated with an increase in paxillin phosphorylation, indicating that p125Fak kinase activity may be stimulated by insulin. Mixing of purified insulin or insulin-like growth factor-I (IGF-I) receptors with p125Fak resulted in an increase in p125Fak phosphorylation. Using a kinase-deficient p125Fak mutant, we found that this protein is a direct substrate of the insulin and IGF-I receptor tyrosine kinases. This view is supported by two additional findings. (i) A peptide corresponding to p125Fak sequence comprising amino acids 568–582, which contains tyrosines 576 and 577 of the kinase domain regulatory loop, is phosphorylated by the insulin receptor; and (ii) p125Fak phosphorylation by the insulin receptor is prevented by addition of this peptide. Finally, we observed that p125Fak phosphorylation by the receptor results in its activation. Our results show that the nature of the cross-talk between the insulin/IGF-I receptors and p125Fak is dependent on the cell architecture, and hence the interaction of the insulin/IGF-I signaling system with the integrin system will vary accordingly.